A Bridge Too Far? Real-World Practice Patterns of Early Glucocorticoid Use in the Canadian Early Arthritis Cohort.


Journal

ACR open rheumatology
ISSN: 2578-5745
Titre abrégé: ACR Open Rheumatol
Pays: United States
ID NLM: 101740025

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 04 05 2021
accepted: 05 08 2021
pubmed: 29 10 2021
medline: 29 10 2021
entrez: 28 10 2021
Statut: ppublish

Résumé

To describe patterns of glucocorticoid use in a large real-world cohort with early rheumatoid arthritis (RA) and assess the impact on disease activity and treatment. Data are from adults with new RA (≤1 year) recruited to the Canadian Early Arthritis Cohort (CATCH) and are stratified on the basis of whether a person was prescribed oral glucocorticoids within 3 months of study entry. Disease activity was compared over 24 months. Mixed-effects logistic regression was used for adjusted odds ratios (aORs) of escalation to biologics separately for 12 and 24 months, with random effects terms to account for prescribing patterns clustering by study site. Among 1891 persons, 30% received oral steroids. Users were older, were less often employed, and had shorter disease duration and higher disease activity. Disease activity improved over time, with early glucocorticoid users starting at higher levels of disease activity. Participants with early oral glucocorticoids were more likely to be on a biologic at 12 months (aOR = 2.4; 95% confidence interval [CI], 1.5-3.7) and 24 months (aOR = 1.9; 95% CI, 1.3-3.0). Despite Canadian clinical practice guidelines to limit corticosteroid use to short-term or 'bridge' therapy, 30% of patients who used oral glucocorticoids still used them 2 years later. Early steroids were prescribed sparingly in CATCH and were often indicative of more active baseline disease as well as the need for progression to biologics.

Identifiants

pubmed: 34708574
doi: 10.1002/acr2.11334
pmc: PMC8754017
doi:

Types de publication

Journal Article

Langues

eng

Pagination

57-64

Subventions

Organisme : The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from: Amgen and Pfizer Canada - Founding sponsors since January 2007; AbbVie Corporation since 2011; Medexus Inc. since 2013; Eli Lilly Canada since 2016, Merck Canada since 2017, Sandoz Canada, Biopharmaceuticals since 2019 and Gilead Sciences Canada since 2020. Previously funded by Hoffmann-LaRoche and Janssen Biotech from 2011-2016, UCB Canada and Bristol-Myers Squ

Investigateurs

Murray Baron (M)
Ines Colmegna (I)
Sabrina Fallavollita (S)
Derek Haaland (D)
Paul Haraoui (P)
Shahin Jamal (S)
Raman Joshi (R)
Ed Keystone (E)
Bindu Nair (B)
Peter Panopoulos (P)
Laurence Rubin (L)
Edith Villeneuve (E)
Michel Zummer (M)

Informations de copyright

© 2021 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.

Références

Ann Rheum Dis. 2016 Jan;75(1):3-15
pubmed: 25969430
Arthritis Rheum. 2005 Nov;52(11):3360-70
pubmed: 16255010
Rheumatology (Oxford). 2006 Sep;45(9):1058-61
pubmed: 16880186
Rheumatology (Oxford). 2013 Jan;52(1):53-61
pubmed: 23192911
J Rheumatol. 2019 Apr;46(4):331-332
pubmed: 30936221
Ann Intern Med. 2012 Mar 6;156(5):329-39
pubmed: 22393128
J Rheumatol. 2012 Nov;39(11):2071-80
pubmed: 22896026
J Manag Care Spec Pharm. 2015 May;21(5):401-7
pubmed: 25943001
Am J Epidemiol. 2003 Nov 1;158(9):915-20
pubmed: 14585769
Rheumatol Ther. 2018 Jun;5(1):255-270
pubmed: 29204858
Arthritis Rheum. 2002 Feb;46(2):347-56
pubmed: 11840436
Lancet. 1997 Aug 2;350(9074):309-18
pubmed: 9251634
Ann Rheum Dis. 2020 Jun;79(6):685-699
pubmed: 31969328
Clin Ther. 2009 Aug;31(8):1871-80; discussion 1858
pubmed: 19808146
Ann Rheum Dis. 2013 Jan;72(1):72-8
pubmed: 22679301
Rheumatology (Oxford). 2014 Jun;53(6):1075-86
pubmed: 24501240
Clin Exp Rheumatol. 2011 Sep-Oct;29(5 Suppl 68):S-5-12
pubmed: 22018177
Am J Epidemiol. 2008 Feb 15;167(4):492-9
pubmed: 18056625
J Rheumatol. 1983 Oct;10(5):713-21
pubmed: 6358491
Ann Rheum Dis. 1964 Mar;23:158-62
pubmed: 14130037
Arthritis Res Ther. 2005;7(4):R796-806
pubmed: 15987481
Arthritis Res Ther. 2011 Aug 31;13(4):R139
pubmed: 21884589
N Engl J Med. 1995 Jul 20;333(3):142-6
pubmed: 7791815
Lancet. 2016 Oct 22;388(10055):2023-2038
pubmed: 27156434
Arthritis Res Ther. 2017 Jul 5;19(1):159
pubmed: 28679392
Arthritis Rheum. 2006 May;54(5):1422-8
pubmed: 16645970
Lancet. 1950 Oct 21;2(6634):483-4
pubmed: 14785191
Ann Rheum Dis. 2010 Apr;69(4):631-7
pubmed: 20215140
Arthritis Rheumatol. 2016 Jan;68(1):1-26
pubmed: 26545940
J Rheumatol. 2019 Apr;46(4):343-350
pubmed: 30275262
PLoS One. 2015 Aug 24;10(8):e0135327
pubmed: 26301589
Ann Rheum Dis. 2013 Dec;72(12):1905-13
pubmed: 23873876
Ann Intern Med. 2002 Jan 1;136(1):1-12
pubmed: 11777359
Lancet. 2008 Jan 19;371(9608):205-14
pubmed: 18207016
Arthritis Rheum. 2005 Nov;52(11):3371-80
pubmed: 16255011
Ann Rheum Dis. 2017 Nov;76(11):1797-1802
pubmed: 28213564
J Manag Care Spec Pharm. 2014 Nov;20(11):1110-20
pubmed: 25351972

Auteurs

Kathleen M Andersen (KM)

Johns Hopkins University, Baltimore, Maryland.

Orit Schieir (O)

University of Toronto, Toronto, Ontario, Canada.

Marie-France Valois (MF)

McGill University, Montreal, Quebec, Canada.

Susan J Bartlett (SJ)

McGill University, Montreal, Quebec, Canada, and Johns Hopkins University, Baltimore, Maryland.

Louis Bessette (L)

Centre Hôspitalier Universitairé de Québec-Université Laval, Québec, Québec, Canada.

Gilles Boire (G)

Université de Sherbrooke, Sherbrooke, Quebec, Canada.

Boulos Haraoui (B)

Institut de Rhumatologie de Montreal, Montreal, Quebec, Canada.

Glen Hazlewood (G)

University of Calgary, Calgary, Alberta, Canada.

Carol Hitchon (C)

University of Manitoba, Winnipeg, Manitoba, Canada.

Edward C Keystone (EC)

Mount Sinai Hospital, Toronto, Ontario, Canada.

Janet Pope (J)

St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada.

Diane Tin (D)

Southlake Regional Health Centre, Newmarket, Ontario, Canada.

J Carter Throne (JC)

Southlake Regional Health Centre, Newmarket, Ontario, Canada.

Vivian P Bykerk (VP)

Hospital for Special Surgery and Weill Cornell Medicine, New York City, New York.

Classifications MeSH